Abstract
Pancreatic cancer is characterized by its insidious onset, which is easy to be present with liver metastasis or other distant organ metastasis at advanced stage, so the prognosis is extremely poor with 5-year survival rate being 4%-6%. Radical resection may be the only curative treatment. How-ever, most patients have lost the chance for surgical resection because of late diagnosis, and the resection rate is less than 20%. What's more, postoperative complications and recurrence make influence on pa-tients' quality of life without significant improvement. For now gemcitabine acting as the gold standard chemotherapy for the treatment of pancreatic cancer, approved by FDA as the first-line chemotherapy drug, can significantly prolong patients' lifetime. Gemcitabine combined with other drugs not only increase the anti-tumor effect, but also decrease the frequency of adverse events and drug resistance. Combination therapy such as gemcitabine+nab-paclitaxel, gemcitabine+erlotinib, gemcitabine+capecitabine have be recommended as the first-line therapy for the treatment of pancreatic cancer by the latest NCCN Guide-lines. This article reviews the most current articles, looking for developments about the gemcitabine-based first-line therapies in order to find better treatment and research strategy of pancreatic cancer. Key words: Gemcitabine; Pancreatic cancer; Combination chemotherapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.